Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literatur zu Thema benigne und maligne Mesotheliome

Autor/en: J.T. Hartmann, C. Bokemeyer
Letzte Änderung: 10.12.2002
  • Achatzy R, Beba W, Titschler R, Worn H, Wahlers B, Macha HN, Morgan JA.
    The diagnosis, therapy and prognosis of diffuse malignant mesothelioma.
    Europ J cardio-thorac Surg 1989;3:455. PM:2635926
    [Medline]


  • Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA.
    Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
    J Clin Oncol 1988;6:527. PM:3351560
    [Medline]


  • Antman KH, Schiff PB, Pass HI:
    Benign and Malignant Mesothelioma.
    In: DeVita et. al (etd.).
    Cancer: Principles & Practice of Oncology, Fifth Ed.
    Lippincott-Raven Publishers, Philadelphia, 1997


  • Antman KH, Shemin R, Ryan L, Klegar KL, Osteen R, Herman T, Lederman GS, Corson J.
    Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades.
    J Clin Oncol 1988;6:147. PM:3335886
    [Medline]


  • Antman KH, Pomfret E, Aisner J, Melntyre J, Osteen RT, Greenberger JS.
    Pertitoneal mesothelioma: natural history and response to chemotherapy.
    J Clin Oncol 1983;1:386. PM:6668506
    [Medline]


  • Antman KH.
    Clinical presentation and natural history of benign and malignant mesothelioma.
    Semin Oncol 1981;8:313. PM:7280715
    [Medline]


  • Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M, et al.
    Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study.
    Cancer 1991;15;67(12):2984-7. PM:2044044
    [Medline]


  • Baas P, Schonwink FA, Zoetmulder FAN.
    Malignant pleural mesothelioma.
    Ann Oncol 1998;9:139-149. PM:9553658
    [Medline]


  • Brandscheid D, Kryasa S, Bauer E, Bülzebruck Hl, Schirren J, Vogt-Moykopf I.
    Diagnostical and therapeutical strategy in malignant pleural mesothelioma.
    Eur J Cardiothorax Surg 1991;5:466-473.


  • Briselli MF, Mark EJ.
    Solitary fibrous tumors of the pleura and benign extrapleural tumors of the pleura and benign extrapleural tumors of mesothelial origin.
    In: Antman K.H., Aisner J. (eds.).
    Asbestos-related malignancy. Grune&Stratton, Orlando: 165, 1987


  • Butchart EG, Ashcroft T, Barnsley WA Holden MP.
    Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura.
    Thorax 1976;31:15-24. PM:1257933
    [Medline]


  • Calavrezos A, Koschel G, Husselmann H.
    Malignant mesothelioma of the pleura.
    Klin Wochenschr 1988;66:607-35. PM:3210656
    [Medline]


  • Castagneto B, Zai S, Botta A, Ardizzoni A, Toma S.
    Intracavitary and systemic IL-2 immunotherapy in malignant pleural mesothelioma.
    Proc Am Soc Clin Oncol 21:31a (119). PM:11165411
    [Medline]


  • Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon JE 2nd, Aisner J, Ellison RR, Leone L, et al.
    Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
    J Clin Oncol 1993;11:1559-65. PM:8336195
    [Medline]


  • Corson J, Pinkus G.
    Cellular localization patterns of keratin proteins in pleural mesothelioma and metastatic adenocarcinoma: a diagnostic discriminant.
    Lab Invest 1991;64:114A.


  • DaValle MJ, Faber LP, Kittle CF, Jensik RJ.
    Extrapleural pneumonectomy for diffuse, malignant mesothelioma.
    Ann Thorac Surg 1986;42:612. PM:2431665
    [Medline]


  • Davis SR, Tan L, Ball DL.
    Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in the palliation.
    Australas Radiolo 1994;38:212. PM:7524472
    [Medline]


  • Daya D, McCaughey WTE.
    Well-differentiated papillary mesothelioma of the peritoneum.
    Cancer 1990;65:292. PM:2295052
    [Medline]


  • Ebert W, Stabrey A, Sibinger M, Schrenk M.
    Value of Pleural Fluid Hyaluronic Acid and Carcinoembryonic Antigen Determination in the Differential Diagnosis between Malignant Mesothelioma and Pleuritis Carcinomatosa. Tumordiagn Ther 1990;12:1-6.


  • Eitner F, Otto H.
    Zur Dignität von Asbestkörperchenzählung im Lungengewebe.
    Arbeitsmed Sozialmed Präventivmed 1984;19:1


  • Groth G, Gatzemeier U, Häussingen K, Heckmayr M, Magnussen H, Neuhauss R, Pavel JV.
    Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone).
    Ann Oncol 1991;2:213-5. PM:1710483
    [Medline]


  • Hilaris BS, Nori D, Kwong E, Kutcher GJ, Martini N.
    Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
    Int J Radiat Oncol Biol Phys 1984;10:325. PM:6706729
    [Medline]


  • Hinds MW.
    Mesothelioma in the United States. Incidence in the 1970's.
    J Occup Med 1978;20:469-471. PM:671123
    [Medline]


  • Kannerstein M, Churg C, McCaughery WTE.
    Asbestos and mesothelioma: a review.
    Pathol Annu 1978;13:81. PM:152898
    [Medline]


  • Kirmani S, Cleory SM, Mowry J, Hawell SB.
    Intracavitary cisplatin for malignant mesothelioma; an update.
    Proc Am Soc Clin Oncol 1988;7:273


  • Krysa S, Schirren J, Schneider P, Trainer S, Bülzebruck H, Vogt-Moykopf I.
    Das diffuse maligne Pleuramesotheliom.
    In: Schmoll et. al.
    Kompendium Internistische Onkologie, 2. Auflage.
    Springer-Verlag, 1997


  • Law MR, Gregor A, Hodson ME, Bloom HJG, Turner-Warwick M.
    Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreted patients.
    Thorax 1984;39:255. PM:6426072
    [Medline]


  • Lee TT, Everett DL, Shu HK, Jahan TM, Roach M 3rd, Speight JL, Cameron RB, Phillips TL, Chan A, Jablons DM.
    Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg 2002;124:1183-9.


  • Liewald F, Sunder-Plassmann L, Dienemann H, Mezger J.
    Das Pleuramesotheliom - Probleme in der Diagnostik und klinischer Verlauf bei 25 Patienten.
    Langenbecks Arch. Chir. 1989;374:105. PM:2704280
    [Medline]


  • Maisch B, Ristic AD, Pankuweit S, Neubauer A, Moll R.
    Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin.
    Eur Heart J 2002;23:1625-31. PM:12323163
    [Medline]


  • Mattson K, Giaccone G, Kirkpatrick A, Evrard D, Tammilehto L, van Breukelen FJ, Planteydt HT, van Zandwijk N.
    Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    J Clin Oncol 1992;10:824-8


  • Mattson K.
    Natural history and clinical staging of malignant mesothelioma.
    Eur J Respir Dis 1982;63:124.


  • Matzel W, Büchel O.
    Diffuse malignant mesothelioma of the pleura - intrapleural treatment with doxorubicin.
    Arch Geschwulstforsch 1987;57:209. PM:3619593
    [Medline]


  • Mezger J, Lamerz R, Bresgen M, Schulz A, Berghäuser K-H, Liewald F, Sunder-Plassmann L, Häussinger KE, Wilmanns W.
    Carcinoembryonales Antigen in Serum und Pleuraerguß zur Unterscheidung von Bronchialkarzinom und Pleuramesotheliom.
    Dtsch med Wschr 1991;116:207. PM:1993432
    [Medline]


  • Montizaan GK, Knaap AGA, Van der Heijden CA.
    Asbestos: toxicology and risk assessment for the general population in the Netherlands.
    FO Chem Toxicol 1989;27:53. PM:2649425
    [Medline]


  • Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW.
    A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.
    Br J Cancer 2002;87:491-6. PM:12189542
    [Medline]


  • Osteen RT.
    Peritoneal mesothelioma.
    In: Antman K.H., Aisner K.H. (eds.).
    Asbestos-Related Malignancy.
    Grune&Stratton, Orlando: 1987; p339.


  • Pass HI.
    Photodynamic theapy for lung cancer.
    Chest surg Clin North Am 1991;1.


  • Pethran A.
    Asbest in der Arbeitswelt - Übersicht über die Möglichkeiten einer Asbeststaubexposition.
    Arbeitsmed Sozialmed Präventivmed 1990;25:446.


  • Pfeifle CE, Howell SB, Markman M.
    Intracavitary cisplatin chemotherapy for mesothelioma.
    Cancer Treat Rep 1985;69:205-207. PM:4038626
    [Medline]


  • Samson MK, Wasser LP, Borden EC, Wanebo HJ, Creech RH, Phillips M, Baker LH.
    Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
    J Clin Oncol 1987;5:86-91. PM:3543239
    [Medline]


  • Samson MK, Baker L, Wasser L.
    Randomized comparison of cyclophosphamide, DTIC and adriamycin versus cyclophosphamide and adriamycin in patients with advanced malignant mesothelioma: a sarcoma intergroup study.
    Proc Am Soc Clin Oncol 1985;4:128. PM:3543239
    [Medline]


  • Selikoff IJ, Hammond EC, Churg J.
    Asbestos exposure, smoking, and neoplasia.
    J Amer med Ass 1968;204:106. PM:5694532
    [Medline]


  • Subramanian R, Flygenring B.
    Mesothelioma of the atrioventricular node and congenital complete heart block.
    Clin Cardiol 1989;12:469. PM:2766593
    [Medline]


  • Sugarbaker D, Harpole D, Healey E, DeCamp M, Mentzner S, Liptay M, Strauss G, Swanson S and Antmann K.
    Multimodality treatment of malignant pleura mesothelioma.
    Proc Am Soc Clin Oncol 1995;14:356.


  • Suzuki Y, Churg C, Kannerstein M.
    Ultrastructure of human malignant diffuse mesothelioma.
    Am J Pathol 1976;85:241. PM:998721
    [Medline]


  • UICC
    Deutsche Ausgabe: TNM-Klassifikation maligner Tumoren, 5. Auflage
    Hrsg: Wittekind CH, Wagner G
    Springer, Berlin Heidelberg New York Tokyo, 1997


  • van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ, van Meerbeeck JP.
    Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.
    Br J Cancer 2002;86:342-5. PM:11875695
    [Medline]


  • Vogelzang NJ, Rusthoven J, Paoletti P, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer MJ, Emri S, Niyikiza C.
    Phase III single-blinded study of pemetrexed + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma.
    Proc Am Soc Clin Oncol 2002;21(5):2a.


  • Vogt-Moykopf I, Etspüler W, Bülzebruck H.
    Das diffuse maligne Pleuramesotheliom - Diagnostik, Therapie und Prognose.
    Z Herz-, Thorax- u Gefäßchir 1987;1:67.


  • Weiss SW, Tavassoli FA.
    Multicystic mesothelioma. An analysis of pathologis findings and biologic behaviour in 37 cases.
    Am J Surg Pathol 1988;12:737. PM:3421410
    [Medline]


  • Weissmann L, Osteen R, Corson J, Herman T, Antman K.
    Combined modality therapy for intraperitoneal mesothelioma.
    Proc Am Soc Clin Oncol 1988;7:274.


  • Woitowitz HJ, Hillerdahl G, Calavrezos A, Berghäuser KH, Rödelsperger K, Jöckel K-H.
    Risiko- und Einflußfaktoren des diffusen malignen Mesothelioms (DMM).
    Schriftenreihe der Bundesanstalt für Arbeitsschutz.
    Verl. f. neue Wissenschaft, Bonn, 1993


  • Woitowitz HJ, Lange HJ, Rödelsperger K, Ulm K, Giesen T, Woitowitz RH, Pache L.
    Berufskrebsstudie Asbest: Möglichkeiten und Grenzen epidemiologischer Todesursachenforschung in der Bundesrepublik Deutschland.
    Dtsch med Wschr 1986;111:490. PM:3956392
    [Medline]


Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]